Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Pembrolizumab
Sponsor: Yonsei University